Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/16606Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Shishoo, C J | - |
| dc.contributor.author | Ravikumar, T | - |
| dc.contributor.author | Jain, K S | - |
| dc.contributor.author | Rathod, I S | - |
| dc.contributor.author | Gandhi, T P | - |
| dc.contributor.author | Satia, M C | - |
| dc.date.accessioned | 2013-03-29T14:35:40Z | - |
| dc.date.available | 2013-03-29T14:35:40Z | - |
| dc.date.issued | 1999-09 | - |
| dc.identifier.uri | http://hdl.handle.net/123456789/16606 | - |
| dc.description | 1075-1085 | en_US |
| dc.description.abstract | A series of novel 1,2-(un)substituted -3-amino-5-aryl-6-arylaminopyrazolo[3,4-d] pyrimidin-4(5H)-ones 5-7 has been synthesised through the cyclocondensation of the corresponding, hitherto unreported 3-aryl-2-arylamino-5-cyano-6- methyl sulfonylpyrimidin-4-ones 3 or 4 with hydrazine hydrate or substituted hydrazines. Compounds 6a and 7a exhibited analgesic activity superior to that of the standards, aspirin & pentazocine. These compounds also exhibited significant antiinflammatory activity comparable to that of diclofenac sodium. The free radical scavenging activity, as well as, the ulcerogenic potential of some of the active compounds in the series was also determined. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | NISCAIR-CSIR, India | en_US |
| dc.rights |  CC Attribution-Noncommercial-No Derivative Works 2.5 India | en_US |
| dc.source | IJC-B Vol.38B(09) [September 1999] | en_US |
| dc.title | Synthesis of novel 1,2-(un) substituted-3-amino-5-aryl-6-arylaminopyrazolo [3,4-d]pyrimidin-4(5H)-ones and their biological activities | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | IJC-B Vol.38B(09) [September 1999] | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJCB 38B(9) 1075-1085.pdf | 2.2 MB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.